JP2012500264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500264A5 JP2012500264A5 JP2011523833A JP2011523833A JP2012500264A5 JP 2012500264 A5 JP2012500264 A5 JP 2012500264A5 JP 2011523833 A JP2011523833 A JP 2011523833A JP 2011523833 A JP2011523833 A JP 2011523833A JP 2012500264 A5 JP2012500264 A5 JP 2012500264A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- treating
- condition
- neurodegeneration
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims 6
- 235000015872 dietary supplement Nutrition 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- AOWPVIWVMWUSBD-UHFFFAOYSA-N 3-hydroxybutyl 3-hydroxybutanoate Chemical group CC(O)CCOC(=O)CC(C)O AOWPVIWVMWUSBD-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000037219 healthy weight Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000011661 metabolic syndrome X Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 238000011301 standard therapy Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9075108P | 2008-08-21 | 2008-08-21 | |
| US61/090,751 | 2008-08-21 | ||
| PCT/US2009/040766 WO2010021766A1 (en) | 2008-08-21 | 2009-04-16 | Hydroxybutyrate ester and medical use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014241939A Division JP6092836B2 (ja) | 2008-08-21 | 2014-11-28 | ヒドロキシ酪酸エステル及びその医学的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012500264A JP2012500264A (ja) | 2012-01-05 |
| JP2012500264A5 true JP2012500264A5 (https=) | 2012-06-07 |
| JP5773870B2 JP5773870B2 (ja) | 2015-09-02 |
Family
ID=40885956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523833A Active JP5773870B2 (ja) | 2008-08-21 | 2009-04-16 | ヒドロキシ酪酸エステル及びその医学的使用 |
| JP2014241939A Active JP6092836B2 (ja) | 2008-08-21 | 2014-11-28 | ヒドロキシ酪酸エステル及びその医学的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014241939A Active JP6092836B2 (ja) | 2008-08-21 | 2014-11-28 | ヒドロキシ酪酸エステル及びその医学的使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (3) | EP4011374A1 (https=) |
| JP (2) | JP5773870B2 (https=) |
| CN (1) | CN102164884B (https=) |
| AU (1) | AU2009283171B2 (https=) |
| CA (1) | CA2734720C (https=) |
| DK (2) | DK2328858T3 (https=) |
| ES (2) | ES2655367T3 (https=) |
| NO (1) | NO2328858T3 (https=) |
| PL (2) | PL3296284T3 (https=) |
| WO (1) | WO2010021766A1 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648952B1 (en) | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| EP2240017B1 (en) | 2008-01-04 | 2019-03-13 | Oxford University Innovation Limited | Ketone bodies and ketone body esters as blood lipid lowering agents |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| GB201002983D0 (en) * | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| US8329938B2 (en) * | 2011-02-21 | 2012-12-11 | Eastman Chemical Company | Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol |
| GB201206192D0 (en) * | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
| DK2914251T3 (da) * | 2012-11-05 | 2019-11-04 | Us Health | Ketonlegemer til beskyttelse af væv mod beskadigelse som følge af ioniseringsstråling |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| GB2515603B (en) * | 2013-03-14 | 2015-10-14 | Isis Innovation | Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate |
| GB201314127D0 (en) * | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
| WO2015156865A1 (en) | 2014-01-13 | 2015-10-15 | University Of South Florida | Methods of sustaining dietary ketosis and its effects on lipid profile |
| CN103860533A (zh) * | 2014-02-12 | 2014-06-18 | 新乡医学院 | β羟基丁酸在治疗帕金森病中的应用 |
| WO2015140752A1 (en) * | 2014-03-19 | 2015-09-24 | Stellenbosch University | Method for treating or enhancing muscle tissue |
| US10245242B1 (en) * | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| CA3021784A1 (en) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| WO2017213999A1 (en) | 2016-06-07 | 2017-12-14 | The J. David Gladstone Institutes | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| AU2017381059B2 (en) * | 2016-12-23 | 2023-11-30 | Katholieke Universiteit Leuven | 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment |
| US12171735B2 (en) | 2017-04-19 | 2024-12-24 | Axcess Global Sciences, Llc | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| GB201710229D0 (en) * | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
| WO2019018683A1 (en) * | 2017-07-21 | 2019-01-24 | Buck Institute For Research On Aging | BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| WO2019147503A1 (en) | 2018-01-25 | 2019-08-01 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| GB2572185A (en) * | 2018-03-21 | 2019-09-25 | Chain Biotechnology Ltd | Pharmaceutical compositions |
| GB2575623B (en) * | 2018-06-04 | 2022-10-26 | Tdeltas Ltd | 3-hydroxybutyrate esters for treating cancer cachexia |
| CA3022995C (en) * | 2018-06-12 | 2019-10-15 | Ketofibe (9211-3133 Quebec Inc.) | Novel ketogenic compounds, compositions, methods and use thereof |
| EP3810120A2 (en) | 2018-06-21 | 2021-04-28 | Société des Produits Nestlé S.A. | Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor |
| GB2577723A (en) | 2018-10-04 | 2020-04-08 | Tdeltas Ltd | Compounds for new use |
| EP3880649B1 (de) * | 2019-01-17 | 2023-03-15 | KetoLipix Therapeutics GmbH | Verfahren zur herstellung von polyolbasierten estern von hydroxycarbonsäuren |
| CN109700021A (zh) * | 2019-03-04 | 2019-05-03 | 清华大学 | 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用 |
| AU2020274805A1 (en) | 2019-05-10 | 2021-10-28 | Ketoswiss Ag | Ketone bodies enclosed in microbeads |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| CN120154071A (zh) * | 2019-05-21 | 2025-06-17 | 雀巢产品有限公司 | 膳食丁酸酯 |
| ES2969217T3 (es) * | 2019-06-12 | 2024-05-17 | Ketolipix Therapeutics Gmbh | Procedimiento para la producción de ésteres a base de poliol, en particular ésteres de poliglicerol, de ácidos hidroxicarboxílicos |
| CN114008014B (zh) * | 2019-06-12 | 2024-03-22 | 凯托利皮克斯治疗有限责任公司 | 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法 |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US12396974B2 (en) | 2020-03-27 | 2025-08-26 | KetoneAid | Ketone ester as a therapeutic treatment of Covid-19 and related viral infections |
| US20230174454A1 (en) * | 2020-05-12 | 2023-06-08 | Genomatica, Inc. | Process of synthesizing and purifying (3r)-hydroxybutyl (3r)-hydroxybutanoate |
| EP4146337B1 (de) * | 2020-07-13 | 2024-04-17 | KetoLipix Therapeutics GmbH | Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren |
| EP4146339B1 (de) * | 2020-07-13 | 2024-04-10 | KetoLipix Therapeutics GmbH | Oxobutanol-ester von polymeren carbonsäuren und deren herstellung |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| CN113045416B (zh) * | 2021-03-23 | 2023-08-18 | 南京纽邦生物科技有限公司 | 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法 |
| WO2023283654A1 (en) * | 2021-07-09 | 2023-01-12 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
| CN117677383A (zh) | 2021-07-17 | 2024-03-08 | 瑞士凯托股份公司 | 酮体或生酮化合物与镇痛剂或抗氧化剂的组合 |
| IT202100020441A1 (it) | 2021-07-30 | 2023-01-30 | Unichem Estense S R L | Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1051853B (it) * | 1975-01-07 | 1981-05-20 | Basf Ag | Butandiol 1.3 3 mono 3 idros sibutirrati butandiol 1.3 1mono 3 idrossibutirrati e processi per la loro preparazione |
| JPH0755158B2 (ja) * | 1986-10-30 | 1995-06-14 | チッソ株式会社 | 光学活性エステルの製造法 |
| BE1001209A3 (fr) * | 1987-11-19 | 1989-08-22 | Solvay | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol. |
| JP4598203B2 (ja) * | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| WO2004105742A1 (en) | 2003-06-02 | 2004-12-09 | Isis Innovation Limited | Treatment of muscle fatigue |
| EP1648952B1 (en) * | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| CA2631264A1 (en) * | 2005-11-29 | 2007-06-07 | Basf Se | Process for esterifying or transesterifying side chains in polymers |
| US8452351B2 (en) * | 2008-06-02 | 2013-05-28 | Qualcomm Incorporated | Methods and apparatus for saving battery power in mobile stations |
-
2009
- 2009-04-16 JP JP2011523833A patent/JP5773870B2/ja active Active
- 2009-04-16 ES ES09789596.5T patent/ES2655367T3/es active Active
- 2009-04-16 EP EP21211530.7A patent/EP4011374A1/en not_active Withdrawn
- 2009-04-16 CA CA2734720A patent/CA2734720C/en active Active
- 2009-04-16 CN CN200980136723.1A patent/CN102164884B/zh active Active
- 2009-04-16 ES ES17176132T patent/ES2907630T3/es active Active
- 2009-04-16 WO PCT/US2009/040766 patent/WO2010021766A1/en not_active Ceased
- 2009-04-16 PL PL17176132T patent/PL3296284T3/pl unknown
- 2009-04-16 DK DK09789596.5T patent/DK2328858T3/en active
- 2009-04-16 DK DK17176132.3T patent/DK3296284T3/da active
- 2009-04-16 NO NO09789596A patent/NO2328858T3/no unknown
- 2009-04-16 EP EP09789596.5A patent/EP2328858B1/en active Active
- 2009-04-16 EP EP17176132.3A patent/EP3296284B1/en active Active
- 2009-04-16 PL PL09789596T patent/PL2328858T3/pl unknown
- 2009-04-16 AU AU2009283171A patent/AU2009283171B2/en active Active
-
2014
- 2014-11-28 JP JP2014241939A patent/JP6092836B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500264A5 (https=) | ||
| JP2020527583A5 (https=) | ||
| WO2012088519A8 (en) | Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders | |
| JP5714227B2 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
| TWI465235B (zh) | Anti-fatigue agent | |
| EA033415B1 (ru) | Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2 | |
| EP3335710A3 (en) | Use of nutritional compositions for preventing disorders | |
| JP2009533356A5 (https=) | ||
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| EP2875736B1 (en) | N-Carbamoylputrescine to enhance muscle protein synthesis | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| IN2014KN02830A (https=) | ||
| WO2010080756A3 (en) | Harmine derivatives for reducing body weight | |
| IN2012DN02590A (https=) | ||
| RU2015129066A (ru) | Применение bifidobacterium animalis для лечения или предотвращения набора веса и инсулинорезистентности | |
| MX2012006734A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. | |
| UA106209C2 (en) | Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid | |
| FI4349369T3 (fi) | Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa | |
| JP2024513567A (ja) | １－メチルキサンチンをベースにした生物活性組成物およびそれを使用する方法 | |
| WO2010107866A3 (en) | Catecholamine derivatives for obesity and neurological disorders | |
| JP2012509669A5 (https=) | ||
| JP2019062914A (ja) | アンモニア代謝促進剤 | |
| TW200621732A (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
| EP2504006B1 (en) | Compositions comprising amino acids for treating chronic obstructive pulmonary disease | |
| WO2011041920A8 (es) | Composición nutracéutica que comprende extracto de shilajit, ácido fólico, vitamina b12 y vitamina b6 y su uso para prevenir y/o tratar enfermedades neurodegenerativas y/o el deterioro cognitivo asociado al envejecimiento cerebral |